METIS Labs can radiolabel your small molecule, antibody, or protein to screen for interactions with thousands of human proteins immobilized on microarray chips. Profiling like this aids with drug target discovery and with target validation (confirm specificity, identify cross-reactions). Two platforms are available: Invitrogen’s ProtoArray® and CDI’s HuProt™ array.
Radiolabeled samples interacting with immobilized proteins produce microscopic spots of varying intensity that we can detect with our digital imaging equipment. The resulting images are processed and statistically analyzed with GenePix®-based software. METIS Labs then produces a detailed report of the profiling experiment and results for the client.
METIS offers a choice of microarrays that allow clients to screen ~45% to ~85% of the entire human proteome in a high throughput methodology. Invitrogen’s ProtoArray® is the most well known and widely used proteomic microarray. CDI’s HuProt™ array is a newer and significantly larger array. About 4,900 proteins are exactly the same on both products; the rest are either variants of the same gene/protein family or uniquely different.